D
Genmab A/S
GMAB
$20.25
$0.050.25%
D
Sell
6/14/2024Downgrade
Genmab A/S (GMAB) was downgraded to D+ from C- on 6/14/2024 due to a decline in the volatility index and total return index.
Genmab A/S (GMAB) was downgraded to D+ from C- on 6/14/2024 due to a decline in the volatility index and total return index.
C
Hold
5/30/2024Upgraded
Genmab A/S (GMAB) was upgraded to C- from D+ on 5/30/2024 due to an increase in the volatility index and valuation index.
Genmab A/S (GMAB) was upgraded to C- from D+ on 5/30/2024 due to an increase in the volatility index and valuation index.
D
Sell
4/11/2024Downgrade
Genmab A/S (GMAB) was downgraded to D+ from C- on 4/11/2024 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from $4.72 to $1.3984, operating cash flow declined 18.86% from $297.48M to $241.38M, and EBIT declined 3.85% from $250.75M to $241.09M.
Genmab A/S (GMAB) was downgraded to D+ from C- on 4/11/2024 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from $4.72 to $1.3984, operating cash flow declined 18.86% from $297.48M to $241.38M, and EBIT declined 3.85% from $250.75M to $241.09M.
C
Hold
12/8/2023Downgrade
Genmab A/S (GMAB) was downgraded to C- from C on 12/8/2023 due to a large decline in the growth index, total return index and volatility index.
Genmab A/S (GMAB) was downgraded to C- from C on 12/8/2023 due to a large decline in the growth index, total return index and volatility index.
C
Hold
8/8/2023Downgrade
Genmab A/S (GMAB) was downgraded to C from C+ on 8/8/2023 due to a noticeable decline in the growth index, efficiency index and volatility index. Operating cash flow declined 86.33% from $466.11M to $63.7M.
Genmab A/S (GMAB) was downgraded to C from C+ on 8/8/2023 due to a noticeable decline in the growth index, efficiency index and volatility index. Operating cash flow declined 86.33% from $466.11M to $63.7M.
C
Hold
4/12/2023Downgrade
Genmab A/S (GMAB) was downgraded to C+ from B- on 4/12/2023 due to a large decline in the total return index and volatility index.
Genmab A/S (GMAB) was downgraded to C+ from B- on 4/12/2023 due to a large decline in the total return index and volatility index.
B
Buy
2/24/2023Downgrade
Genmab A/S (GMAB) was downgraded to B- from B on 2/24/2023 due to a large decline in the growth index and total return index. Operating cash flow declined 79.49% from $266.54M to $54.67M, and earnings per share declined from $5.305 to $1.2135.
Genmab A/S (GMAB) was downgraded to B- from B on 2/24/2023 due to a large decline in the growth index and total return index. Operating cash flow declined 79.49% from $266.54M to $54.67M, and earnings per share declined from $5.305 to $1.2135.
B
Buy
1/11/2023Upgraded
Genmab A/S (GMAB) was upgraded to B from B- on 1/11/2023 due to a major increase in the total return index and volatility index.
Genmab A/S (GMAB) was upgraded to B from B- on 1/11/2023 due to a major increase in the total return index and volatility index.
B
Buy
1/4/2023Upgraded
Genmab A/S (GMAB) was upgraded to B- from C+ on 1/4/2023 due to a noticeable increase in the total return index, growth index and volatility index. Operating cash flow increased 94.13% from $137.3M to $266.54M, EBIT increased 46.49% from $178.53M to $261.52M, and earnings per share increased from $4.1032 to $5.305.
Genmab A/S (GMAB) was upgraded to B- from C+ on 1/4/2023 due to a noticeable increase in the total return index, growth index and volatility index. Operating cash flow increased 94.13% from $137.3M to $266.54M, EBIT increased 46.49% from $178.53M to $261.52M, and earnings per share increased from $4.1032 to $5.305.
C
Hold
10/21/2022Upgraded
Genmab A/S (GMAB) was upgraded to C+ from C on 10/21/2022 due to an increase in the total return index.
Genmab A/S (GMAB) was upgraded to C+ from C on 10/21/2022 due to an increase in the total return index.
C
Hold
10/6/2022Downgrade
Genmab A/S (GMAB) was downgraded to C from C+ on 10/6/2022 due to a decline in the total return index.
Genmab A/S (GMAB) was downgraded to C from C+ on 10/6/2022 due to a decline in the total return index.
C
Hold
9/21/2022Upgraded
Genmab A/S (GMAB) was upgraded to C+ from C on 9/21/2022 due to an increase in the total return index.
Genmab A/S (GMAB) was upgraded to C+ from C on 9/21/2022 due to an increase in the total return index.
C
Hold
8/15/2022Downgrade
Genmab A/S (GMAB) was downgraded to C from C+ on 8/15/2022 due to a decline in the total return index.
Genmab A/S (GMAB) was downgraded to C from C+ on 8/15/2022 due to a decline in the total return index.
C
Hold
6/17/2022Upgraded
Genmab A/S (GMAB) was upgraded to C+ from C on 6/17/2022 due to an increase in the volatility index.
Genmab A/S (GMAB) was upgraded to C+ from C on 6/17/2022 due to an increase in the volatility index.
C
Hold
5/6/2022Downgrade
Genmab A/S (GMAB) was downgraded to C from C+ on 5/6/2022 due to a noticeable decline in the volatility index and valuation index.
Genmab A/S (GMAB) was downgraded to C from C+ on 5/6/2022 due to a noticeable decline in the volatility index and valuation index.
C
Hold
2/25/2022Downgrade
Genmab A/S (GMAB) was downgraded to C+ from B- on 2/25/2022 due to a large decline in the growth index, total return index and volatility index. Operating cash flow declined 47.67% from $70.84M to $37.07M, earnings per share declined from $2.1347 to $1.6646, and EBIT declined 11.77% from $141.04M to $124.44M.
Genmab A/S (GMAB) was downgraded to C+ from B- on 2/25/2022 due to a large decline in the growth index, total return index and volatility index. Operating cash flow declined 47.67% from $70.84M to $37.07M, earnings per share declined from $2.1347 to $1.6646, and EBIT declined 11.77% from $141.04M to $124.44M.
B
Buy
2/7/2022Downgrade
Genmab A/S (GMAB) was downgraded to B- from B on 2/7/2022 due to a large decline in the growth index, total return index and valuation index.
Genmab A/S (GMAB) was downgraded to B- from B on 2/7/2022 due to a large decline in the growth index, total return index and valuation index.
B
Buy
7/30/2021Upgraded
Genmab A/S (GMAB) was upgraded to B from B- on 7/30/2021 due to a noticeable increase in the total return index and efficiency index. Net income increased 90.92% from $93.04M to $177.63M, and total capital increased 0.57% from $3.21B to $3.23B.
Genmab A/S (GMAB) was upgraded to B from B- on 7/30/2021 due to a noticeable increase in the total return index and efficiency index. Net income increased 90.92% from $93.04M to $177.63M, and total capital increased 0.57% from $3.21B to $3.23B.
B
Buy
3/8/2021Downgrade
Genmab A/S (GMAB) was downgraded to B- from B on 3/8/2021 due to a decline in the total return index, volatility index and efficiency index.
Genmab A/S (GMAB) was downgraded to B- from B on 3/8/2021 due to a decline in the total return index, volatility index and efficiency index.
B
Buy
12/14/2020Upgraded
Genmab A/S (GMAB) was upgraded to B from B- on 12/14/2020 due to an increase in the volatility index.
Genmab A/S (GMAB) was upgraded to B from B- on 12/14/2020 due to an increase in the volatility index.
B
Buy
11/5/2020Downgrade
Genmab A/S (GMAB) was downgraded to B- from B on 11/5/2020 due to a large decline in the growth index, total return index and solvency index. Earnings per share declined from $7.5844 to $1.263, EBIT declined 79.71% from $664.21M to $134.79M, and total revenue declined 66.36% from $805.12M to $270.83M.
Genmab A/S (GMAB) was downgraded to B- from B on 11/5/2020 due to a large decline in the growth index, total return index and solvency index. Earnings per share declined from $7.5844 to $1.263, EBIT declined 79.71% from $664.21M to $134.79M, and total revenue declined 66.36% from $805.12M to $270.83M.
B
Buy
9/18/2020None
Genmab A/S (GMAB) was downgraded to B from U on 09/18/2020.
Genmab A/S (GMAB) was downgraded to B from U on 09/18/2020.
NASDAQ
03/19/2025 4:00PM Eastern
Quotes delayed
